Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Rare Disease

Rare Disease

Drug development success hinges on simplifying Clinical Research

May 16th, 2019 | Rare Disease

Strategic Consulting: The convergence revolution to innovate clinical trial process

May 10th, 2019 | Rare Disease

Strategic Consulting – SCIO Process -A New Way for Drug Development

April 30th, 2019 | Rare Disease

Strategic consulting reduces cost and risk of clinical trials

April 2nd, 2019 | Rare Disease

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Rare Disease

Welcome to BBCR’s New Website!

December 7th, 2018 | Rare Disease
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.
  • Accelerate Drug Development with Biomarker Strategy in Orphan Diseases and Precision Medicine
  • At BBCR, our team of seasoned experts is dedicated to helping clients navigate the intricate landscape of rare genetic conditions and unsolved diseases. We work hand in hand with product developers to create the most effective strategies for bringing innovative treatments to market.
  • Our experienced CRO Management and Drug development team identify study remediation strategies and provide a resource for any Study Rescue. We invite you to reach out to learn more – visit bbcrconsulting.com.
  • A pioneering figure in the area of rare diseases and orphan drug early-stage clinical research and regulatory strategies, Dr. Candida Fratazzi has an impressive 25-year track record in this specialized field.

RSS Nasdaq Globe Newswire

  • BioStem Technologies Appoints Brandon Poe as Chief Financial Officer August 14, 2025
  • Plant Biotechnology Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Crop Protection, Seeds, and Sustainable Farming Solutions August 14, 2025
  • Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update August 14, 2025
  • Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 August 14, 2025
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2025 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs